The Protocol Review and Monitoring Committee (PRMC) provides full scientific review and monitors the progress of and accrual to all cancer clinical protocols Involving patients that are conducted in Dan L Duncan Cancer Center (DLDCC)-affiliated Institutions. PRMC functions are complementary to, but do not overlap those of the Data Safety Monitoring Committee and the IRB. The PRMS reviews all therapeutic and prevention clinical trials whose primary aim Is cancer related. The PRMC Is organized Into an Executive Committee and three working groups, with a total of 45 voting members. The Executive Committee chaired by Dr Stacey Berg the PRMC director assigns each protocol a scientific merit score of 1-9 based on NIH review descriptors as well as DLDCC priority scores of High, Medium, and Low at initial review to aid In prioritization. At the time of each open protocol's annual IRB review, the PRMC Executive Committee conducts a full review to ensure that adequate scientific progress is being made. In addition, the Executive Committee reviews the accrual to all the open protocols in each Program on a quarterly basis. In the 12 month period from July 2008 to June 2009 the PMRC reviewed 50 new protocols including 10 institutional protocols of which 6 were approved pending modification, 3 were tabled, and 1 was disapproved. The PMRC monitored 32 Institutional protocols during this period for performance closing 3 for slow accrual or because new scientific information lowered the priority of the study. The PRMC provides reports to the Clinical Research Leadership Committee which also receives reports from the Data Safety Monitoring Committees ensuring that activities of these two separate entitles are integrated.

Public Health Relevance

The Protocol Review and Monitoring Committee of the Dan L Duncan Cancer Center ensures that all clinical protocols at the center undergo a rigorous scientific review prior to opening and also monitors studies to ensure that they still have scientific relevance and are accruing subjects at the projected rate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-07
Application #
8515965
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
7
Fiscal Year
2013
Total Cost
$92,058
Indirect Cost
$46,524
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Gibbons, Don L; Creighton, Chad J (2018) Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. Dev Dyn 247:555-564
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
McClard, Cynthia K; Kochukov, Mikhail Y; Herman, Isabella et al. (2018) POU6f1 Mediates Neuropeptide-Dependent Plasticity in the Adult Brain. J Neurosci 38:1443-1461
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Amirian, E Susan; Ostrom, Quinn T; Armstrong, Georgina N et al. (2018) Aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis. Cancer Epidemiol Biomarkers Prev :
Mishra, Prachi; Tang, Wei; Putluri, Vasanta et al. (2018) ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming. J Clin Invest 128:323-340
Piyarathna, Danthasinghe Waduge Badrajee; Rajendiran, Thekkelnaycke M; Putluri, Vasanta et al. (2018) Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus 4:907-915
Criglar, Jeanette M; Anish, Ramakrishnan; Hu, Liya et al. (2018) Phosphorylation cascade regulates the formation and maturation of rotaviral replication factories. Proc Natl Acad Sci U S A 115:E12015-E12023
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Ostrom, Quinn T; Kinnersley, Ben; Armstrong, Georgina et al. (2018) Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. Int J Cancer 143:2359-2366

Showing the most recent 10 out of 991 publications